Home> Products> robust glycemic control

{ "products": [ { "_id": "66619278db9fdd21801ef284", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.3 ", "description": "SEIZMET TRIO 0.3 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.3mg)\nIntroduction to SEIZMET TRIO 0.3\nSEIZMET TRIO 0.3 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.3 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.3\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.3 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.3 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.3 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.3 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-3-133446", "price": 166.9, "discountamount": 50.07, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "3", "day", "body", "Diet", "EMAIL", "Order", "liver", "water", "meals", "amount", "slower", "option", "Action", "Support", "Overview", "pancreas", "readings", "digestion", "biguanide", "Voglibose", "one tablet", "lower rise", "overweight", "Guidelines", "full glass", "neuropathy", "utilization", "Adjustments", "information", "retinopathy", "Optimal Use", "Introduction", "Metformin SR", "SEIZMET TRIO", "best results", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1453, "imageuri": "https://productimages.withfloats.com/actual/6661927b487c46164ce4b1f6.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661927b487c46164ce4b1f6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:42:00.595Z", "updatedon": "2024-06-29T07:23:34.909Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-trio-0-3-/1453", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.3", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.3mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666191664515df1748621e0b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.2 ", "description": "SEIZMET TRIO 0.2 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.2mg)\nIntroduction to SEIZMET TRIO 0.2\nSEIZMET TRIO 0.2 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.2mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.2 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.2\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.2 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.2 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.2 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.2 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-2-133445", "price": 155.9, "discountamount": 46.77, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "Diet", "body", "liver", "meals", "water", "Order", "EMAIL", "option", "amount", "slower", "Action", "Support", "readings", "Overview", "pancreas", "Improved", "Voglibose", "digestion", "biguanide", "neuropathy", "full glass", "lower rise", "overweight", "one tablet", "Guidelines", "information", "Adjustments", "retinopathy", "utilization", "Optimal Use", "Metformin SR", "best results", "Introduction", "SEIZMET TRIO", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1452, "imageuri": "https://productimages.withfloats.com/actual/6661916a8e77bb2c7156e563.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661916a8e77bb2c7156e563.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:37:26.597Z", "updatedon": "2024-06-29T07:23:47.697Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-trio-0-2-/1452", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.2 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.2", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.2mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665efdbd66170d1ff8cb13bf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA 3D 10/100/500 SR ", "description": "GLIDAPA 3D 10/100/500 SR \nDapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg\nIntroduction\nGLIDAPA 3D 10/100/500 SR is a sophisticated, multi-mechanism oral medication designed for the management of Type 2 diabetes. It combines Dapagliflozin (10 mg), Sitagliptin (100 mg), and Metformin (500 mg, sustained release), offering a robust, integrated approach to controlling high blood glucose levels.\n\nMechanism of Action\n\nDapagliflozin (10 mg): As an SGLT2 inhibitor, Dapagliflozin promotes the excretion of glucose through urine by blocking its reabsorption in the kidneys. This helps to lower blood sugar levels and also has benefits for weight loss and cardiovascular health.\nSitagliptin (100 mg): A DPP-4 inhibitor, Sitagliptin works by enhancing the body's own ability to lower blood glucose levels in response to meals. It does this by increasing the levels of incretin hormones, which affect the pancreas to produce more insulin and less glucagon.\nMetformin SR (500 mg): Metformin works primarily by reducing glucose production in the liver, improving insulin sensitivity, and lowering glucose absorption in the gut. The sustained-release (SR) formulation ensures a steady release over time, minimizing gastrointestinal side effects and maintaining more consistent blood sugar control.\nBenefits\nGLIDAPA 3D 10/100/500 SR provides a comprehensive treatment solution by addressing several key pathways in glucose metabolism, thereby reducing the risk of both hyperglycemia and associated complications. The combination of these three active substances in a single formulation enhances convenience and potentially improves adherence to treatment protocols.\n\nDosage and Administration\n\nDosage: The recommended starting dose depends on the patient’s current treatment regimen and their specific health profile. Adjustments should be made based on effectiveness and tolerability, under the guidance of a healthcare professional.\nAdministration: This medication should be taken once daily in the morning, with or without food. The tablet should be swallowed whole to maintain the sustained release of Metformin.\nSide Effects\nPossible side effects of GLIDAPA 3D 10/100/500 SR include urinary tract and genital infections (due to Dapagliflozin), nausea or a sore throat (from Sitagliptin), and digestive issues such as diarrhea or abdominal pain (common with Metformin). Most side effects are manageable and tend to decrease over time.\n\nConclusion\nGLIDAPA 3D 10/100/500 SR is a versatile and effective option for those managing Type 2 diabetes, offering triple-action treatment in one convenient medication. It targets various aspects of diabetes management, improves glycemic control, and enhances overall quality of life. Patients are advised to maintain regular follow-ups with their healthcare provider to optimize treatment outcomes and manage any side effects.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/glidapa-3d-10-100-500-sr-134215", "price": 575.0, "discountamount": 172.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "gut", "time", "life", "risk", "food", "body", "urine", "liver", "EMAIL", "Order", "meals", "500 mg", "nausea", "tablet", "patient", "ability", "kidneys", "morning", "response", "diarrhea", "pancreas", "guidance", "benefits", "adherence", "versatile", "excretion", "Conclusion", "sore throat", "Sitagliptin", "weight loss", "Adjustments", "combination", "information", "convenience", "Introduction", "sterispharma", "Metformin SR", "reabsorption", "sterisonline", "urinary tract", "CALL/WHATSAPP", "hyperglycemia", "Dapagliflozin", "less glucagon", "effectiveness", "starting dose", "abdominal pain", "steady release", "overall quality", "SGLT2 inhibitor", "various aspects", "Type 2 diabetes", "DPP-4 inhibitor", "Dapaflozin 10 mg", "effective option", "digestive issues", "glycemic control", "Most side effects", "sustained release", "incretin hormones", "regular follow-ups", "genital infections", "blood sugar levels", "glucose metabolism", "glucose absorption", "glucose production", "treatment outcomes", "single formulation", "diabetes management", "insulin sensitivity", "healthcare provider", "treatment protocols", "several key pathways", "Administration Dosage", "Possible side effects", "cardiovascular health", "triple-action treatment", "specific health profile", "three active substances", "healthcare professional", "associated complications", "GLIDAPA 3D 10/100/500 SR", "current treatment regimen", "one convenient medication", "high blood glucose levels", "robust, integrated approach", "gastrointestinal side effects", "consistent blood sugar control", "comprehensive treatment solution", "sustained-release (SR) formulation", "sophisticated, multi-mechanism oral medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1300, "imageuri": "https://productimages.withfloats.com/actual/665efdc0e874b19df8b5f4ce.png", "tileimageuri": "https://productimages.withfloats.com/tile/665efdc0e874b19df8b5f4ce.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:42:53.803Z", "updatedon": "2024-06-04T11:42:53.803Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-3d-10-100-500-sr-/1300", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIDAPA 3D 10/100/500 SR ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665ef5bda743fd235821deeb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE M 80 ", "description": "GLICLAGLAZE M 80 \ngliclazide (80mg),Metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 80 is a specialized medication formulated for individuals diagnosed with Type 2 diabetes, aiming to enhance blood sugar regulation. This oral medication combines Gliclazide (80 mg) with Metformin (500 mg), two effective antidiabetic agents that provide a synergistic effect to control high blood sugar.\n\nMechanism of Action\n\nGliclazide (80 mg): Belonging to the sulfonylurea class, Gliclazide works by increasing insulin secretion from the pancreatic beta cells. It promotes a decrease in blood glucose levels and enhances the action of insulin in the body. Additionally, Gliclazide improves blood flow and has protective effects against the vascular complications of diabetes.\nMetformin (500 mg): Metformin reduces hepatic glucose production and improves insulin sensitivity by enhancing peripheral glucose uptake, particularly in muscle cells. This action helps lower blood glucose levels without the risk of inducing hypoglycemia and is associated with a potential reduction in body weight.\nBenefits\nGLICLAGLAZE M 80 offers a robust approach to managing Type 2 diabetes by targeting different aspects of the disease. The combination of Gliclazide and Metformin in this medication helps to control blood sugar more effectively than either component alone, potentially lowering the patient's risk of diabetes-related complications.\n\nDosage and Administration\n\nDosage: The starting dose should be adjusted based on the patient’s previous medication regimen, effectiveness, and tolerability. Dose adjustments should be made based on glycemic control, as assessed by regular monitoring of blood glucose levels.\nAdministration: It is recommended to take GLICLAGLAZE M 80 with meals to maximize drug absorption and minimize potential gastrointestinal side effects.\nSide Effects\nPotential side effects of GLICLAGLAZE M 80 include gastrointestinal symptoms like nausea and diarrhea, which usually improve over time. The risk of hypoglycemia exists but is moderated by the inclusion of Metformin.\n\nConclusion\nGLICLAGLAZE M 80 represents an effective treatment solution for managing Type 2 diabetes, combining two powerful antidiabetic agents to improve glycemic control and reduce the risk of diabetes complications. Patients should maintain regular consultations with their healthcare provider to tailor their treatment plan according to their specific needs, ensuring the best possible outcomes in diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-m-80-133420\n\n\n\n\n\n", "price": 137.0, "discountamount": 41.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "risk", "time", "Order", "meals", "EMAIL", "nausea", "500 mg", "Action", "patient", "disease", "diarrhea", "Benefits", "decrease", "Mechanism", "Metformin", "component", "inclusion", "Conclusion", "blood flow", "gliclazide", "individuals", "information", "body weight", "combination", "Introduction", "muscle cells", "tolerability", "sterispharma", "hypoglycemia", "sterisonline", "starting dose", "effectiveness", "CALL/WHATSAPP", "GLICLAGLAZE M", "treatment plan", "specific needs", "Type 2 diabetes", "oral medication", "robust approach", "drug absorption", "high blood sugar", "Dose adjustments", "glycemic control", "different aspects", "insulin secretion", "regular monitoring", "sulfonylurea class", "synergistic effect", "protective effects", "healthcare provider", "insulin sensitivity", "potential reduction", "diabetes management", "blood glucose levels", "regular consultations", "pancreatic beta cells", "Administration Dosage", "best possible outcomes", "blood sugar regulation", "Potential side effects", "specialized medication", "diabetes complications", "vascular complications", "gastrointestinal symptoms", "peripheral glucose uptake", "hepatic glucose production", "previous medication regimen", "effective treatment solution", "diabetes-related complications", "two powerful antidiabetic agents", "two effective antidiabetic agents", "potential gastrointestinal side effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1287, "imageuri": "https://productimages.withfloats.com/actual/665ef5c0ca75628a5853ff45.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef5c0ca75628a5853ff45.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:08:45.584Z", "updatedon": "2024-06-04T11:08:45.584Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-m-80-/1287", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE M 80 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Imatinib IP 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2025-12-18T07:41:25.851Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/imatinib-ip-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "691f0bfb7357125af3e94c2b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sucralfate Tinidazole and Povidone Iodine Ointment", "description": "Sucralfate, Tinidazole, and Povidone Iodine Ointment is an advanced multi-action topical formulation designed to promote rapid wound healing, prevent infection, and enhance tissue regeneration. This combination therapy is widely used in dermatology, surgery, gynecology, and general wound management due to its broad-spectrum antimicrobial activity and strong healing-supportive characteristics. Each active ingredient plays a unique and complementary role, making this ointment highly effective in managing acute and chronic wounds, ulcers, burns, and infected skin lesions.\n\nAt the core of the formulation, Sucralfate acts as a protective barrier over damaged tissues. It binds to proteins at the wound site, forming a protective layer that shields the area from external irritants and bacterial contamination. This barrier not only promotes faster healing but also enhances tissue regeneration by stimulating growth factors and improving blood supply to the injured surface.\n\nTinidazole, a potent antiprotozoal and antibacterial agent, further strengthens the formulation by targeting anaerobic bacteria and protozoa commonly responsible for wound infections. Its inclusion helps reduce microbial load, prevent secondary infections, and create an ideal environment for clean and complication-free healing.\n\nFinally, Povidone Iodine, a trusted antiseptic, provides broad-spectrum germicidal action against bacteria, fungi, viruses, and spores. It effectively reduces wound contamination, minimizes odor, and prevents colonization of harmful microorganisms. Together, these ingredients create a synergistic effect that supports comprehensive wound management.\n\nProduct Uses\n\nThis ointment is commonly prescribed for:\n\nDiabetic foot ulcers\nHelps control infection while promoting tissue repair in complex ulcers.\n\nPressure sores and bedsores\nProvides protection and healing acceleration for chronic wounds.\n\nBurns (first and second degree)\nPrevents infection and reduces healing time.\n\nMinor cuts, abrasions, and skin injuries\nIdeal for daily wound care and minor trauma.\n\nPost-surgical wounds\nHelps prevent infection and supports clean healing.\n\nInfected wounds or skin lesions\nEffective against wounds contaminated with anaerobic bacteria or other pathogens.\n\nGynecological wound care\nMay be used for episiotomy care or infected perineal wounds under medical supervision.\n\nKey Benefits\n1. Broad-Spectrum Antimicrobial Protection\n\nThe combination of Tinidazole and Povidone Iodine provides robust defense against bacteria, fungi, protozoa, and viruses, significantly reducing infection risk.\n\n2. Accelerated Healing and Tissue Regeneration\n\nSucralfate forms a protective layer that maintains moisture balance, promotes granulation tissue formation, and speeds up recovery.\n\n3. Reduced Inflammation and Discomfort\n\nBy minimizing bacterial load and shielding damaged tissues, the ointment helps reduce redness, swelling, and pain.\n\n4. Ideal for Complex and Chronic Wounds\n\nEspecially effective for ulcers, burns, and infected wounds where multiple layers of treatment are needed.\n\n5. Odor Control in Infected Wounds\n\nPovidone Iodine’s antimicrobial action helps reduce foul odor associated with infected or necrotic tissue.\n\n6. Safe and Well-Tolerated\n\nWhen used as directed, this combination ointment is suitable for a wide range of patients, including those with difficult-to-heal wounds.\n\nPossible Side Effects\n\nWhile generally safe, some individuals may experience:\n\nMild skin irritation or redness\n\nBurning or stinging sensation at the application site\n\nDryness or peeling of skin\n\nAllergic reactions (rare), such as rash or itching\n\nTemporary discoloration of skin due to Povidone Iodine\n\nSensitivity reactions in iodine-allergic individuals\n\nPatients with thyroid disorders, severe burns, or extensive wounds should use Povidone Iodine-containing products only under medical guidance.\n\nConclusion\n\nSucralfate, Tinidazole, and Povidone Iodine Ointment stands out as a highly effective and versatile wound-care solution. Its triple-action design—protective, antimicrobial, and regenerative—makes it ideal for managing complicated wounds, preventing infection, and supporting faster, cleaner healing. Whether used for chronic ulcers, burns, surgical wounds, or everyday skin injuries, this formulation offers a reliable and scientifically supported approach to comprehensive wound management. With its blend of protection, infection control, and healing enhancement, it remains a valuable tool for both healthcare professionals and patients seeking superior wound-care outcomes.", "price": 98.0, "discountamount": 29.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2214, "imageuri": "https://productimages.withfloats.com/actual/691f0bfde83a250c0e084bb9.png", "tileimageuri": "https://productimages.withfloats.com/tile/691f0bfde83a250c0e084bb9.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-20T12:39:23.314Z", "updatedon": "2025-11-29T06:52:45.216Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sucralfate-tinidazole-and-povidone-iodine-ointment/2214", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Steris Healthcare Pvt. Ltd", "category": "Gerneral", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6911af10f122e2a45d230b07", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 2 mg", "description": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg is a triple-combination oral anti-diabetic medication formulated to achieve optimal blood sugar control in adults with Type 2 Diabetes Mellitus (T2DM). This unique blend brings together three complementary agents — Sitagliptin (a DPP-4 inhibitor), Metformin (a biguanide), and Glimepiride (a sulfonylurea) — that work through distinct mechanisms to enhance glucose regulation, improve insulin sensitivity, and support overall metabolic balance.\n\nThis advanced combination therapy is prescribed when monotherapy or dual therapy fails to achieve adequate glycemic control. It helps reduce both fasting plasma glucose (FPG) and postprandial glucose (PPG) levels, promoting stable long-term glycemic management.\n\nUses of Sitagliptin + Metformin + Glimepiride\n\nThis fixed-dose combination is primarily indicated for the management of Type 2 Diabetes Mellitus in adults. It is especially beneficial for patients whose blood sugar levels remain uncontrolled despite treatment with Metformin and Glimepiride or Metformin and Sitagliptin alone.\n\nIts main objectives include:\n\nControlling elevated blood glucose levels in adults with Type 2 diabetes\n\nReducing the risk of diabetes-related complications such as neuropathy, nephropathy, and cardiovascular diseases\n\nSupporting better insulin utilization by the body\n\nComplementing diet, exercise, and lifestyle modification to maintain optimal glycemic balance\n\nMechanism of Action\n\nEach component of this combination plays a vital role in maintaining blood sugar control:\n\nSitagliptin (50 mg) – A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the activity of incretin hormones. These hormones stimulate insulin release and suppress glucagon production when blood glucose levels rise, thereby improving post-meal glucose control.\n\nMetformin Hydrochloride (1000 mg) – A biguanide that lowers glucose production in the liver and increases the body’s sensitivity to insulin. It also decreases intestinal glucose absorption, making it an essential first-line therapy in diabetes management.\n\nGlimepiride (2 mg) – A sulfonylurea that stimulates pancreatic beta cells to release more insulin, especially when blood glucose levels are high. It works synergistically with Metformin and Sitagliptin for more effective glycemic control.\n\nKey Benefits\n\nTriple Mechanism for Superior Control:\nBy combining three potent agents, the medication addresses multiple pathways of glucose regulation—insulin secretion, insulin sensitivity, and hepatic glucose output—resulting in comprehensive and consistent control of blood sugar levels.\n\nEffective Glycemic Stability:\nThe combination helps maintain target HbA1c levels and reduces both fasting and post-meal glucose spikes without significant weight gain when used with proper diet and exercise.\n\nReduced Risk of Diabetic Complications:\nLong-term blood sugar control minimizes the risk of complications such as kidney disease, vision problems, nerve damage, and heart conditions associated with uncontrolled diabetes.\n\nConvenient Fixed-Dose Formulation:\nCombining three medications into a single tablet simplifies dosing schedules, improves patient adherence, and reduces pill burden, which is crucial for long-term treatment success.\n\nImproved Insulin Efficiency:\nEnhances the body's natural insulin response and glucose metabolism, allowing for smoother daily energy levels and reduced fatigue associated with hyperglycemia.\n\nPossible Side Effects\n\nWhile this combination is generally well tolerated, some patients may experience side effects, especially at the beginning of therapy. Common and rare side effects include:\n\nHypoglycemia (low blood sugar): More likely when meals are skipped or during excessive physical exertion. Symptoms include sweating, dizziness, and rapid heartbeat.\n\nGastrointestinal disturbances: Such as nausea, vomiting, diarrhea, abdominal discomfort, or loss of appetite (mostly due to Metformin).\n\nHeadache or Weakness: Usually mild and transient.\n\nAllergic reactions: Rarely, rash or itching may occur.\n\nLactic Acidosis (rare but serious): A potential complication of Metformin, particularly in patients with kidney impairment or excessive alcohol consumption.\n\nWeight gain: Mild weight gain may occur due to Glimepiride’s insulin-enhancing effect.\n\nPrecautions:\n\nRegular monitoring of blood sugar levels and kidney function is essential.\n\nAvoid alcohol and consult a doctor before using this medicine if you have liver or kidney disease.\n\nThe medication should not be used in patients with Type 1 diabetes or diabetic ketoacidosis.\n\nConclusion\n\nThe combination of Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg represents a powerful and balanced therapy for adults with Type 2 Diabetes Mellitus, especially those requiring triple-drug intervention to achieve desired glycemic control. Its multi-targeted approach ensures effective management of both fasting and postprandial glucose levels, thereby improving long-term metabolic health and reducing the risk of complications.", "price": 295.0, "discountamount": 89.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2197, "imageuri": "https://productimages.withfloats.com/actual/6911af137e4c90e1dc453884.png", "tileimageuri": "https://productimages.withfloats.com/tile/6911af137e4c90e1dc453884.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-10T09:23:28.795Z", "updatedon": "2025-12-09T05:58:38.882Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-2-mg/2197", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+2 ", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg", "anti-diabetic medication", "blood sugar control", "Type 2 Diabetes Mellitus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68fcb453ba48b3ee8857fd47", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin Phosphate Monhydrate 64.25 mg, Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 1 mg", "description": "ST GLIPTIN GM is a high-quality, fixed-dose combination oral antidiabetic medication containing Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 1 mg. This triple-combination therapy is specifically formulated to provide effective glycemic control in adults with type 2 diabetes mellitus (T2DM) who require multiple agents to achieve adequate blood sugar control.\nST GLIPTIN GM works through complementary mechanisms to target the core pathophysiological defects of T2DM—insulin resistance, impaired insulin secretion, and increased hepatic glucose output—making it an ideal choice for patients requiring intensified therapy.\nKey Indications:\nST GLIPTIN GM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when dual therapy with any two of the individual components (Sitagliptin, Metformin, or Glimepiride) does not provide adequate control.\nMechanism of Action:\nSitagliptin (50 mg):\nA Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the levels of active incretin hormones (GLP-1 and GIP), increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.\nMetformin Hydrochloride (1000 mg):\nA biguanide that improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake.\nGlimepiride (1 mg):\nA sulfonylurea that stimulates pancreatic β-cells to secrete insulin, thereby reducing blood glucose levels.\nThe combination targets multiple metabolic pathways to provide synergistic and sustained blood glucose control.\nDosage and Administration:\nRecommended Dose:\nOne tablet daily, preferably with meals to reduce gastrointestinal side effects.\nIndividualization Required:\nDosage should be tailored based on patient response, renal function, and physician assessment.\nRenal Monitoring:\nBaseline and periodic assessment of renal function is advised, particularly due to the metformin component.\nKey Benefits of ST GLIPTIN GM 50/1000/1:\nTriple Mechanism of Action:\nTargets insulin resistance, insufficient insulin secretion, and excessive hepatic glucose production.\nEnhanced Glycemic Control:\nEffective in achieving and maintaining HbA1c targets.\nOnce-Daily Convenience:\nImproves adherence by reducing pill burden in patients requiring combination therapy.\nWeight Neutral to Modest Reduction:\nMetformin and sitagliptin components support weight neutrality.\nLow Hypoglycemia Risk:\nSitagliptin and metformin carry minimal hypoglycemia risk; however, glimepiride may increase the risk—monitor accordingly.\nSafety and Precautions:\nHypoglycemia:\nMay occur, particularly due to the glimepiride component. Educate patients on recognizing and managing low blood sugar.\nLactic Acidosis:\nA rare but serious complication of metformin. Avoid in patients with significant renal impairment or conditions predisposing to hypoxia.\nRenal Function:\nDose adjustment or discontinuation may be needed based on renal function.\nPancreatitis:\nRare reports with DPP-4 inhibitors like sitagliptin. Discontinue if suspected.\nAllergic Reactions:\nDiscontinue use if hypersensitivity reactions occur.\nPossible Side Effects:\nWhile ST GLIPTIN GM is generally well-tolerated, some patients may experience:\nNausea\nDiarrhea\nHeadache\nHypoglycemia (especially in elderly or with missed meals)\nAbdominal discomfort\nUpper respiratory tract infections\nDizziness\nFlatulence\nIf any side effects persist or worsen, seek immediate medical advice.\nStorage Instructions:\nStore at a temperature below 30°C.\nProtect from moisture and direct sunlight.\nKeep out of reach of children.\nWhy Choose ST GLIPTIN GM 50/1000/1?\nST GLIPTIN GM provides a powerful and synergistic combination of three well-established antidiabetic agents in a single, convenient daily dose. It offers a comprehensive approach to managing type 2 diabetes by addressing multiple metabolic abnormalities with a focus on safety, efficacy, and patient compliance. Manufactured under stringent GMP-certified conditions, ST GLIPTIN GM ensures quality, reliability, and therapeutic confidence for both patients and prescribers.", "price": 285.0, "discountamount": 86.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2188, "imageuri": "https://productimages.withfloats.com/actual/68fcb456f31288eaa96accfa.png", "tileimageuri": "https://productimages.withfloats.com/tile/68fcb456f31288eaa96accfa.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-25T11:28:19.425Z", "updatedon": "2025-12-09T06:06:38.819Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-phosphate-monhydrate-64-25-mg-sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-1-mg/2188", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+1", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin 50 mg", "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 1 mg", "type 2 diabetes mellitus (T2DM)", "blood sugar control" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-12-02T06:31:16.051Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }